Entrada Therapeutics Target Price

See Entrada Therapeutics's analyst price targets ($14) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.64

Average Target Price

$14.00

110.8% upside

2 analysts in the last 4 months

High: $17 | Low: $11

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-12	Roth Capital	$11	65.7% upside
2026-06-08	Guggenheim	$17	156% upside
2026-05-08	Roth Capital	$10	50.6% upside
2026-02-10	Guggenheim	$20	201.2% upside
2026-01-28	OppenheimerKostas Biliouris	$21	216.3% upside
2025-11-06	Roth Capital	$13	95.8% upside
2025-02-28	Roth Capital	$23	246.4% upside
2024-11-06	H.C. WainwrightBoobalan Pachaiyappan	$20	201.2% upside
2024-06-25	H.C. WainwrightRaghuram Selvaraju	$18	171.1% upside

Entrada Therapeutics (TRDA) FAQ

Entrada Therapeutics posts a target price of $14. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $14 for TRDA means covering analysts, on average, see the stock 110.8% upside of $6.64 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for TRDA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Entrada Therapeutics's other metric pages and overview cover the third.